Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Non-Hodgkin's lymphomas, version 1.2013.

Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Mar 1;11(3):257-72; quiz 273.

PMID:
23486452
2.

A case of hepatitis B reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin's lymphoma patient.

Wu C, Shi H, Lu M, Xu Y, Chen X.

Virol Sin. 2013 Feb;28(1):49-52. doi: 10.1007/s12250-013-3285-x. Epub 2013 Feb 6. No abstract available.

PMID:
23385354
3.

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.

Ann Hematol. 2004 Jan;83(1):58-60. Epub 2003 Sep 26.

PMID:
14513286
4.
5.

Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with acute promyelocytic leukemia treated with arsenic trioxide.

Yujiri T, Tanaka M, Taguchi A, Tanaka Y, Nakamura Y, Tanizawa Y.

Ann Hematol. 2014 Feb;93(2):351-2. doi: 10.1007/s00277-013-1804-3. Epub 2013 Jun 1. No abstract available.

PMID:
23728611
6.

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.

Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.

Ann Hematol. 2011 Oct;90(10):1219-23. doi: 10.1007/s00277-011-1241-0. Epub 2011 Apr 26.

PMID:
21520001
7.

Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma.

Yavuz S, Paydas S, Disel U, Sahin B.

Leuk Lymphoma. 2003 Jul;44(7):1249-50. No abstract available.

PMID:
12916882
8.

Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.

Matsui T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Andoh S, Sakai H, Maemori M, Maguchi H, Tanaka Y.

J Med Virol. 2013 Nov;85(11):1900-6. doi: 10.1002/jmv.23694. Epub 2013 Aug 7.

PMID:
23926082
9.

Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.

Niscola P, Del Principe MI, Maurillo L, Venditti A, Buccisano F, Piccioni D, Amadori S, Del Poeta G.

Leukemia. 2005 Oct;19(10):1840-1. No abstract available.

PMID:
16094417
10.

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.

Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M.

BMC Gastroenterol. 2014 Feb 17;14:31. doi: 10.1186/1471-230X-14-31.

11.

Non-Hodgkin's Lymphomas, version 3.2012.

Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA.

J Natl Compr Canc Netw. 2012 Dec 1;10(12):1487-98.

PMID:
23221787
12.

Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph.

Becker N, Schnitzler P, Boffetta P, Brennan P, Foretova L, Maynadié M, Nieters A, Staines A, Benavente Y, Cocco P, de Sanjose S.

J Cancer Res Clin Oncol. 2012 Dec;138(12):1993-2001. doi: 10.1007/s00432-012-1279-y. Epub 2012 Jul 6.

PMID:
22767316
13.

[Anomalous serological pattern of hepatitis B virus in 2 patients treated with alemtuzumab].

García-Lozano T, Aznar-Oroval E, Guerrero-Zotano Á.

Rev Esp Quimioter. 2013 Sep;26(3):228-9. Spanish. No abstract available.

14.

Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.

Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B.

Haematologica. 2003 Nov;88(11):1296-303.

15.
16.

A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K.

Bone Marrow Transplant. 2001 Feb;27(4):433-6.

17.

Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma.

Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL.

Br J Haematol. 2002 Jan;116(1):166-9.

PMID:
11841412
18.

Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.

Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, Cheong JW, Lee ST, Min YH.

Yonsei Med J. 2007 Feb 28;48(1):78-89.

19.

Viral genomes and antigen detection of hepatitis B and C viruses in involved lymph nodes of Egyptian non-Hodgkin's lymphoma patients.

El-Sayed GM, Mohamed WS, Nouh MA, Moneer MM, El-Mahallawy HA.

Egypt J Immunol. 2006;13(1):105-14.

PMID:
17974155
20.

Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma.

Gozdas HT, Arpaci E.

World J Gastroenterol. 2015 Sep 21;21(35):10251-2. doi: 10.3748/wjg.v21.i35.10251.

Supplemental Content

Support Center